Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Rises By 1,923.2%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a large increase in short interest in August. As of August 31st, there was short interest totaling 15,579 shares, an increase of 1,923.2% from the August 15th total of 770 shares. Based on an average daily volume of 17,581 shares, the short-interest ratio is presently 0.9 days. Currently, 0.9% of the shares of the stock are sold short.

Bolt Biotherapeutics Trading Up 2.9%

BOLT stock opened at $3.84 on Friday. Bolt Biotherapeutics has a 12-month low of $3.13 and a 12-month high of $7.20. The business’s 50-day moving average is $3.87 and its 200 day moving average is $4.34. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 1.47. The stock has a market cap of $7.41 million, a price-to-earnings ratio of -0.23 and a beta of 1.09.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its earnings results on Tuesday, August 11th. The company reported ($4.57) earnings per share for the quarter, missing the consensus estimate of ($3.39) by ($1.18). The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.50 million. Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 126.23%. On average, sell-side analysts anticipate that Bolt Biotherapeutics will post -11.1 EPS for the current fiscal year.

Institutional Investors Weigh In On Bolt Biotherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Squarepoint Ops LLC grew its holdings in shares of Bolt Biotherapeutics by 19.8% during the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after buying an additional 2,448 shares in the last quarter. Shay Capital LLC acquired a new stake in Bolt Biotherapeutics in the 3rd quarter valued at about $85,000. Susquehanna International Group LLP purchased a new position in Bolt Biotherapeutics in the 3rd quarter worth approximately $89,000. Nano Cap New Millennium Growth Fund L P purchased a new position in Bolt Biotherapeutics in the 4th quarter worth approximately $112,000. Finally, T3 Companies LLC purchased a new stake in shares of Bolt Biotherapeutics in the fourth quarter valued at approximately $208,000. Institutional investors and hedge funds own 86.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Friday, July 17th. Finally, Rodman & Renshaw started coverage on Bolt Biotherapeutics in a research note on Thursday, May 28th. They set a “buy” rating and a $22.00 target price for the company. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $14.50.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.